Lorena Diéguez,
Leader of the Medical Devices Research Group,
INL- International Iberian Nanotechnology Laboratory
Lorena Diéguez joined INL in 2014 as a Staff Researcher and is, since 2018, the leader of the Medical Devices research group. Her research is mainly devoted to Translational Medical Research in close collaboration with hospitals and focuses on the development of tools and solutions based on microfluidics, biosensors and nanotechnology towards early diagnosis and better understanding of diseases. She is also very interested in translating her technology from the lab to the clinic and is co-founder and CEO of the spin-off company RUBYnanomed in the field of liquid biopsy. Currently, she is also the Chair of the Working Group in Medical Devices at the ETPN (European Technology Platform in Nanomedicine). She obtained her Bachelors in Physics with a Major in Optoelectronics at the University of Santiago de Compostela in 2005, then completed her Masters in Nanotechnology at the University of Barcelona (UB) in 2007 and her PhD in Biosensors at the UB, the Institute for Bioengineering of Catalonia and the ETH Zürich. Her postdoc at the University of South Australia (2010-2013) was devoted to the study of rare cells from biological samples using microfluidics.
Using Microfluidics for Non-Invasive Cancer Diagnosis
Wednesday, 9 September 2020 at 09:30
Add to Calendar ▼2020-09-09 09:30:002020-09-09 10:30:00Europe/LondonUsing Microfluidics for Non-Invasive Cancer DiagnosisPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Microfluidics presents numerous advantages for the handling of
biological samples, as it provides careful control of fluids in the
microscale. When it comes to biomarkers enrichment, microfluidics has
demonstrated superior sensitivity and enhanced recovery compared to
traditional methods. Incorporating sensors, lab-on-a-chip technologies
offer efficient characterization of disease biomarkers from body fluids,
making microfluidics ideal for clinical practice, enabling high
throughput, portability, and automation. Early dissemination of cancer
is difficult to detect by traditional imaging and pathological methods.
While the presence of cancer material in body fluids is well known,
current techniques for the isolation, analysis and characterization of
these biomarkers are not efficient enough to be fully applied in
clinical routine. In this talk, we present our work for isolation and
multiplex analysis of cancer biomarkers from body fluids based on
microfluidics, and biosensors towards personalized medicine and earlier
diagnosis of cancer.
Add to Calendar ▼2020-09-09 00:00:002020-09-10 00:00:00Europe/LondonPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020Point-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2020-09-09 09:30:002020-09-09 10:30:00Europe/LondonUsing Microfluidics for Non-Invasive Cancer DiagnosisPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
